More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

“Even in individuals who had not yet developed kidney disease, we could see that kidney function was linked to brain atrophy.

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

Researchers at Lund University in Sweden have made a major breakthrough in diagnosing Lewy body disease, a leading cause of ...

In a new study, published in The Journal of the Alzheimer's Association, researchers discovered CMV, a type of herpesvirus, ...